Trinity Biotech Launches Next-Gen HbA1c System in Brazil After Regulatory Nod
Event summary
- Trinity Biotech began commercial rollout of its Premier Hb9210 HbA1c column system in Brazil on March 12, 2026, following local regulatory approval.
- The system is the only one globally to receive IFCC Gold classification for 2026, recognizing top-tier clinical accuracy.
- Brazil has 16-18 million adults with diabetes, making it a critical market for Trinity Biotech's diabetes management solutions.
- Bruna Gigliotti was appointed to lead Trinity Biotech's Brazilian commercial operations.
The big picture
Trinity Biotech's expansion into Brazil with its next-generation HbA1c system positions it in one of the world's largest diabetes markets. The IFCC Gold classification underscores the system's technical superiority, particularly valuable in Brazil's genetically diverse population where hemoglobin variants are prevalent. This move aligns with broader industry trends toward more precise diabetes management solutions and highlights Trinity Biotech's strategic focus on high-growth international markets.
What we're watching
- Market Penetration
- How quickly Trinity Biotech can gain market share in Brazil's competitive diabetes diagnostics space.
- Regulatory Advantage
- Whether the IFCC Gold classification will translate into meaningful competitive differentiation.
- Execution Risk
- The effectiveness of Bruna Gigliotti's leadership in driving local commercial success.
Related topics